Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Nakamura, Minoru; Kondo, Hisayoshi; Mori, Tsuyoshi; Komori, Atsumasa; Matsuyama, Mutsumi; Ito, Masahiro; Takii, Yasushi; Koyabu, Makiko; Yokoyama, Terufumi; Migita, Kiyoshi; Daikoku, Manabu; Abiru, Seigo; Yatsuhashi, Hiroshi; Takezaki, Eiichi; Masaki, Naohiko; Sugi, Kazuhiro; Honda, Koichi; Adachi, Hiroshi; Nishi, Hirofumi; Watanabe, Yukio; Nakamura, Yoko; Shimada, Muneaki; Komatsu, Tatsuji; Saito, Akira; Saoshiro, Takeo; Harada, Hideharu; Sodeyama, Takeshi; Hayashi, Shigeki; Masumoto, Akihide; Sando, Takehiro; Yamamoto, Takakazu; Sakai, Hironori; Kobayashi, Masakazu; Muro, Toyokichi; Koga, Michiaki; Shums, Zakera; Norman, Gary L.; Ishibashi, Hiromi

doi:10.1002/hep.21472

Cited by 325 publications

(315 citation statements)

References 43 publications

Supporting

Mentioning

269

Contrasting

Unclassified

Order By: Relevance

“…1,2 Hepatic failure is recognized as the most severe part of a clinical spectrum that serves as a strong indicator for liver transplantation. [1][2][3][4][5] Because PBC is serologically characterized by the presence of antimitochondrial antibodies, which are present in more than 90% of patients before the appearance of clinical signs or symptoms, this serological hallmark is used as a biomarker for the diagnosis of PBC patients. 5,6 However, this marker is not associated with progression of PBC.…”

mentioning

confidence: 99%

“…[1][2][3][4][5] Because PBC is serologically characterized by the presence of antimitochondrial antibodies, which are present in more than 90% of patients before the appearance of clinical signs or symptoms, this serological hallmark is used as a biomarker for the diagnosis of PBC patients. 5,6 However, this marker is not associated with progression of PBC. [5][6][7][8][9][10] Furthermore, antinuclear antibodies are also specifically detected in approximately 50% of PBC patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis

Ohishi¹,

Nakamura²,

Iio³

et al. 2008

Hepatology

Self Cite

View full text Add to dashboard Cite

Primary biliary cirrhosis (PBC) is a multifactorial disease in which genetic factors rather than environmental factors may predominantly contribute to the pathogenesis. In order to identify the genetic determinants of the disease severity and progression of PBC, we examined an association of seven tag single-nucleotide polymorphisms (SNPs) in the multidrug resistance protein 3 (MDR3/ABCB4) gene in 148 Japanese PBC patients and 150 age-and sex-matched healthy control subjects. SNPs were detected via polymerase chain reaction (PCR) restriction fragment length polymorphism and PCR direct DNA sequencing methods. Subsequently, haplotypes were constructed from three tag SNPs (rs31658, rs31672, and rs1149222) that were significantly associated with progression of PBC. Logistic regression analyses revealed that a Hap 2 haplotype and its homozygous diplotype, Hap 2/Hap 2, in MDR3 were closely associated with the susceptibility to jaundice-type progression of PBC [P ‫؍‬ 0.004, odds ratio (

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis

Ohishi¹,

Nakamura²,

Iio³

et al. 2008

Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although a serological hallmark of PBC is the presence of AMA, which is found in >90% of patients, ANAs are also detected in PBC patients [13][14][15][16][17]. Anti-gp210 and anti-sp100 antibodies are highly specific for PBC and useful for its diagnosis, particularly those who are negative for AMAs [13][14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…Anti-gp210 and anti-sp100 antibodies are highly specific for PBC and useful for its diagnosis, particularly those who are negative for AMAs [13][14][15][16][17]. In addition, although AMAs are not associated with disease progression, ANAs are associated with disease severity and are therefore useful as a marker of poor prognosis [15][16][17][18].…”

Section: Discussionmentioning

confidence: 99%